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Abstract 
Background: Neurosyphilis might be difficult to diagnose particularly in asymptomatic patients and patients with 
HIV-coinfection. The objective of this study was to evaluate current diagnostic standards for neurosyphilis in HIV-
positive and -negative patients.
Methods: We studied retrospectively patients with an active syphilis infection who had additionally undergone 
lumbar puncture. Patients where the criteria for the diagnosis of a definite or probable neurosyphilis were applicable 
were further analyzed for clinical symptoms, CSF, HIV-status as well as Treponema pallidum testing in serum and CSF. 
Correlation analysis of categorical variables was done by using the Chi-square test or in cases of small sample sizes the 
exact test of Fisher. p values ≤0.05 were considered significant.
Results: Eighty-nine patients were diagnosed with syphilis. All necessary criteria for the diagnosis of a neurosyphilis 
were available in 67 of them including 35 HIV-positive and 32 HIV-negative patients. A definite neurosyphilis could be 
retrospectively diagnosed in 13 and a probable in another 25 cases. Normal CSF results were more likely in HIV-nega-
tives (p = 0.016). A neurosyphilis was correlated to a CSF pleocytosis > 5 cells/µl and to an albumin quotient >7.8 mg/
dl regardless of a parallel HIV infection. HIV-positives had more frequently a CSF-RPR titre >1:4 than HIV-negatives 
(p = 0.031). However, the RPR test in CSF in definite or probable neurosyphilis had a sensitivity of only 21 %.
Discussion: Our data show that a pleocytosis and an elevated albumin quotient correlate with neurosyphilis. How-
ever, the CSF-RPR test as gold standard in neurosyphilis diagnostics has a very low sensitivity.
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Background
The incidence of syphilis rises especially in patients with 
a high risk for HIV [1–6]. Neurosyphilis might be difficult 
to diagnose particularly in asymptomatic patients and 
patients with HIV coinfection. It was shown that the HI-
viral load during a syphilis infection is higher than with-
out coinfection and moreover, it decreases when syphilis 
is treated [7]. Additionally even without a syphilis infec-
tion, HIV-infected patients often show a CSF pleocyto-
sis and an increased protein level [8]. The importance 
of considering HIV-coinfection as an important factor 
for the development of neurosyphilis was displayed in a 
study by Lynn and Lightman in 2004. They detected that 
23.5 % of untreated patients with HIV-coinfection had a 
neurosyphilis while this applied to only 10 % of untreated 
patients without HIV [9].
According to the German guidelines, the diagnosis of 
neurosyphilis is based on clinical symptoms and exami-
nation of the cerebrospinal fluid (CSF) for inflammatory 
parameters and treponemal and non-treponemal tests 
like TPPA-, RPR-, and FTA-ABS test. However, a pleocy-
tosis and elevated CSF-protein can indicate neurosyphilis 
although it is difficult to discriminate between alterations 
due to HIV-infection or Neurosyphilis. Another param-
eter indicating neurosyphilis is a positive CSF-TPPA- 
or -FTA-ABS test. The activity of neurosyphilis can be 
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confirmed by a positive CSF-VDRL or CSF-RPR although 
it is important to be aware of the tests sensitivity which 
ranges between 27 and 70 % [8, 10, 11].
Another parameter which is included in the German 
guidelines for “sexually transmitted diseases for diagnosis 
and therapy in syphilis” to diagnose neurosyphilis is the 
TPPA- or ITPA index. It is calculated by using the TPPA-
titre in relation to the IgG-values in serum and CSF. Its 
sensitivity is higher than the sensitivity of the CSF-VDRL 
but it is not suitable as a parameter for activity [8, 10–12]. 
Only a positive CSF-VDRL- or -RPR-test result is suitable 
to confirm activity as well as specific IgM-antibodies in 
CSF or a pleocytosis. In addition to that a blood-CSF bar-
rier disturbance should be taken into account [12].
Regarding this it would be useful to find predictive 
parameters for neurosyphilis. Lately a number of CD4+ 
T cells <350/μl and a serum RPR-titre >1:32 were inter-
preted as predictive [13–15].
The objective of this study was to evaluate current 
diagnostic standards for their sensitivity and specificity 
in serum and cerebrospinal fluid (CSF) in HIV-positive 
and -negative patients with active syphilis and to evaluate 
predictive factors for neurosyphilis.
Methods
We screened electronic medical files of the Charité Hos-
pital from 2000 to 2012 for patients with a confirmed 
active syphilis infection who had undergone lumbar 
puncture.
All patients had a positive TPPA-titre (≥1:80) and 
positive FTA-ABS OR IgM-FTA-ABS in serum. Patients 
where the criteria for the diagnosis of a definite or prob-
able neurosyphilis were applicable were further analyzed.
We searched the medical records for HIV-status and 
for clinical symptoms such as focal deficits (i.e. dysar-
thria/aphasia, vertigo, cognitive impairment, ocular 
involvement, gait disturbance, hemiplegia, incontinence, 
and cranial nerve palsy), affective signs (i.e. depression), 
pain (i.e. neuropathic pain, headache), fatigue, quantita-
tive disturbance of consciousness and seizures.
We analyzed the CSF for cell count, albumin quotient, 
protein content, glucose, lactate, oligoclonal bands and 
quantitative IgG, IgM and IgA and considered a CSF 
protein level >50  mg/dl OR albumin quotient >7.8 as a 
blood-CSF barrier disturbance. Furthermore we built 
subpopulations regarding the inflammatory response [1: 
inflammatory CSF (pleocytosis with/without blood-CSF 
barrier disturbance), 2: pure blood-CSF barrier distur-
bance, 3: intrathecal immunoglobulin synthesis, 4: nor-
mal CSF].
We also analyzed the CSF and serum for Treponema 
pallidum specific tests by using Treponema pallidum 
particle agglutination test (Serodia® TP·PA), Rapid 
Plasma Reagin-test (RPR-nosticon® II, BioMérieux) and 
IgM-ELISA or 19S-IgM-FTA-ABS test and also the ITPA 
index.
Criteria of a neurosyphilis were retrospectively applied 
to the patients. According to the Guideline of the Ger-
man Sexually Transmitted Diseases Society for diagno-
sis and therapy of syphilis we used the following criteria 
to diagnose a definite neurosyphilis [12]: ITPA index >2 
AND positive CSF-IgM-FTA ABS OR CSF-RPR-titre 
>1:1 OR an inflammatory CSF syndrome (pleocytosis >4 
cells/µl OR blood-CSF barrier disturbance).
Neurosyphilis was probable if two of the first three fol-
lowing conditions were fulfilled and in addition to that 
the 4th condition always had to be fulfilled [12]:
1. Chronically progressive course of neurologic-psychi-
atric symptoms with phases of aggravation and partly 
remission.
2. Pathological CSF with mixed cellular or mononu-
clear pleocytosis (>4 cells/μl), blood-CSF barrier dis-
turbance (CSF-protein >0.5  g/l or albumin quotient 
>7.8) and/or IgG-dominant immune response in cen-
tral nervous system.
3. Beneficial effect of antibiotics on the course of the 
disease and/or pathological CSF (particularly pleocy-
tosis and barrier disturbance).
4. Positive TPHA (or TPPA) and FTA-abs in serum.
The 4th condition applied to all of our patients since it 
was a criterion for inclusion in this study. The 3rd con-
dition cannot be evaluated retrospectively because the 
course of the disease was not observed. Patients who met 
the first two criteria were regarded as patients with prob-
able neurosyphilis. We did not use the diagnosis of neu-
rosyphilis by a clinician as a parameter.
The ethics committee of the Charité School of Medi-
cine in Berlin approved the study. The general terms of 
data protection and the Charité ‘Good Medical and Sci-
entific Practice’ statutes were applied.
Statistics
We used SPSS 18® for statistical analysis. Scaled variables 
were tested by Shapiro–Wilk-test for normal distribu-
tion. The Mann–Whitney U test for independent sam-
ples was used to compare these variables in the group 
of HIV-positive and HIV-negative patients. Correla-
tion analysis of categorical variables was done by using 
the Chi-squared test or in cases of small sample size the 
exact test of Fisher. Multivariate analysis was done by 
binary logistic regression analysis. p values ≤0.05 were 
considered significant.
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Results
We found 89 patients who were diagnosed with active 
syphilis and underwent lumbar puncture at Charité Ber-
lin between 2000 and 2012. These included 80 male and 
9 female patients. Retrospectively we were able to get 
information about the HIV-status for 75 of these indi-
viduals including 39 HIV-positive and 36 HIV-negative 
patients. The following results are based on the analysis 
of these according to the available criteria to diagnose 
either definite or probable neurosyphilis.
Furthermore all necessary criteria for the diagnosis of 
a definite or probable neurosyphilis were available in 67 
of them including 35 HIV-positive and 32 HIV-negative 
patients. Criteria for a definite neurosyphilis could be 
retrospectively fulfilled by 13 cases with six HIV-positive 
and six HIV-negative men and one HIV-negative woman. 
Criteria for a probable neurosyphilis were fulfilled by 
another 25 cases including one HIV-negative woman and 
24 men, of whom 17 are HIV-positive and 7 HIV-nega-
tive (Table 1).
Differences between HIV‑positives and HIV‑negatives
Thirteen patients fulfilled the criteria of a definite neuro-
syphilis. Half of the HIV-positive patients (3/6) have been 
asymptomatic for neurological symptoms while the HIV-
negatives have been symptomatic in all cases (7/7).
Further we found no difference in neurological clini-
cal symptoms between HIV-positive and HIV-negative 
patients with either definite or probable neurosyphilis 
(p  =  0.264). However the clinical spectrum had a very 
wide range and the subpopulations were too small to 
reach statistical significance.
Cerebrospinal fluid
The protein level overall was higher in HIV-positives 
(p  =  0.002) with a mean of 128.4  mg/dl (23–928  mg/
dl) in comparison with HIV-negatives with a mean of 
71.5 mg/dl (14–437 mg/dl). Dividing into subgroups with 
or without neurosyphilis, the difference between HIV-
negatives and -positives becomes hardly insignificant. 
Without neurosyphilis the mean protein level in HIV-
positives was 126.8 mg/dl (23–650 mg/dl) and 60.6 mg/dl 
(25–389 mg/dl) in HIV-negatives (p = 0.064). With defi-
nite neurosyphilis the mean protein level was 115.5 mg/
dl (44–194 mg/dl) in HIV-positives and 57.7 mg/dl (14–
149 mg/dl) in HIV-negatives (p = 0.063).
The mean cell count in CSF was 60 cells/µl (0–511 
cells/µl) in HIV-positives and 19 cells/µl (1–165 cells/µl) 
Table 1 Treponema pallidum testing and  CSF characteristics in  individuals with  a retrospectively definite or probable 
neurosyphilis divided according to HIV status
neg. negative, pos. positive, n.a. not available
Neurosyphilis+ Neurosyphilis−
N = 38 N = 29
HIV+ HIV− HIV+ HIV−
N = 23 N = 15 N = 12 N = 17
n n n n
CSF cell count in cells/µl (mean/range) 87 (1–511) 23 32 (4–165) 15 9 (0–33) 11 9 (1–50) 16
n.a. 1 n.a. 1
CSF Protein in mg/dl (mean/range) 129 (40–928) 23 86 (14–437) 15 145 (23–650) 11 43 (25–60) 16
1 n.a. 1
Albumin quotient in (mean/range) 12 (3.2–31.4) 20 8.4 (2.7–15.9) 14 6.1 (3.1–15.7) 11 6.4 (3.6–10.7) 14
n.a. 3 n.a. 1 n.a. 1 n.a. 3
Oligoclonal bands in CSF pos. 11 pos. 8 pos. 9 pos. 6
neg. 8 neg. 5 neg. 2 neg. 8
n.a. 4 n.a. 2 n.a. 1 n.a. 3
Serum RPR (median/range) 1:32 (1:1–1:1024) 21 1:16 (1:2–1:512) 13 1:32 (1:4–1:128) 11 1:16 (1:2–1:256) 14
2 neg. 2 neg. 1 neg. 2 neg.
CSF RPR (median/range) 1:8 (1:8–1:512) 5 1:2/1:4 (1:1–1:4) 4 neg. 12 neg. 16
neg. 18 neg. 11 pos. 1
ITPA index (mean/range) 4.1 (0–30.9) 21 5 (0.1–15.2) 13 0.9 (0–5.8) 12 1 (0.1–3.7) 16
n.a. 2 n.a. 2 n.a. 1
CD4 cell count in cells/µl (mean/range) 333 (60–780) 18 – – 320 (41–611) 10 – –
n.a. 5 n.a. 2
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in HIV-negatives. We found a mean albumin quotient 
of 9.5  mg/dl (3.1–31.4  mg/dl) in HIV-positive patients 
and a mean albumin quotient of 7.2 (2.7–15.9 mg/dl) in 
HIV-negatives.
We identified a total of 50 patients with an inflamma-
tory CSF (group 1). Among these we found 28 patients 
with HIV and 22 HIV-negative patients. HIV-positives 
and -negatives did not differ in the frequency of occur-
rence of an inflammatory CSF (p = 0.226).
Patients with pure blood-CSF barrier disturbance with-
out any other abnormalities in CSF were included in the 
second group. This applied to four patients including 
exclusively HIV-positive patients. Nevertheless, there 
is no significant difference between HIV-positives and 
HIV-negatives, which we assume is due to the small sam-
ple size (p = 0.076).
An isolated immunoglobulin synthesis with oligoclonal 
bands or quantitative synthesis of IgG and/or IgM in 
CSF (group 3) was found in eight patients. Among these 
were five HIV-positive patients and three HIV-negative 
patients. Again, the difference between the two subpopu-
lations was insignificant (p = 0.420).
A normal CSF (group 4) was found in seven patients, 
all of whom were HIV-negative. HIV-negative patients 
had significantly more often a normal CSF than HIV-pos-
itive patients (p = 0.003).
Subgroups with good or poor immune status defined 
by CD4+ cell counts
Furthermore we divided the HIV-positive patients with 
available CD4+  cell  counts (n  =  32) in those with a 
good immune status defined by CD4+cells above 350/
µl and those with a significantly impaired immune status 
defined by a CD4+ cell count ≤350/µl.
We found 16 patients with good immune status with a 
mean CD4+ cell count of 546 cells/µl (357–810 cells/µl) 
and 16 patients with poor immune status with a mean of 
167 cells/µl (41–288 cells/µl).
28 Of those 32 HIV-positive patients could be analyzed 
according to the necessary data to diagnose either defi-
nite or probable neurosyphilis. We discovered a signifi-
cant difference in the occurrence of headache (p = 0.022) 
and neurological symptoms (p = 0.037) which were both 
more likely in patients with CD4+  cell  count ≤350/µl. 
There was no difference in diagnostic parameters to be 
found.
Predictive factors for neurosyphilis
Another objective was to evaluate predictive factors for 
neurosyphilis. We therefore analyzed only those 28 patients 
with available CD4+  cell  count and all necessary crite-
ria for the diagnosis of definite or probable neurosyphilis. 
We calculated the positive predictive value of the serum 
RPR-titre ≥1:32 as well as of the CD4+  cell  count for a 
definite or probable neurosyphilis. The first reached a posi-
tive predictive value of 71.4 % and the second had a value 
of 66.7 %. The calculated positive predictive value of those 
two parameters in combination was 66.7  %, however the 
sensitivity of both parameters in combination increased 
to 77.8  % in comparison to considering both separately 
(55.6 % for both parameters). Considering this we cannot 
give the advice to use a poor CD4+  cell  count or a high 
RPR-titre to predict a neurosyphilis (Table 2).
We tried to find other parameters in serum to pre-
dict neurosyphilis by using regression analysis for TPPA 
test, RPR test, IgM-FTA-ABS test, CD4+  cell count, 
HI-viral-load in serum and HIV-status. None of these 
showed a significant correlation with definite or prob-
able neurosyphilis. Our data shows rather how impor-
tant it is to look for more suitable parameters to predict a 
neurosyphilis.
We therefore evaluated parameters in CSF which might 
correlate with definite or probable neurosyphilis in 67 
patients with known HIV-status who had all necessary cri-
teria for the diagnosis of definite or probable neurosyphi-
lis available. We found blood-CSF barrier disturbance 
(p  =  0.001), albumin quotient >7.8  mg/dl (p  =  0.0002), 
CSF pleocytosis >5 cells/µl (p =  0.0002), local IgG-syn-
thesis (p  =  0.047), CSF-TPPA ≥1:32 (p  =  0.007), ITPA 
index >2 (p = 0.042) and positive IgM-FTA-ABS in CSF 
(p =  0.016) to be correlated. Those patients had signifi-
cantly more often a definite or probable neurosyphilis.
A disturbed blood-CSF barrier significantly correlates 
with a definite or probable neurosyphilis for HIV-posi-
tives (p = 0.027, odds ratio 6.0) as well as for HIV-neg-
atives (p  =  0.018, odds ratio 9.0). The same applies for 
an albumin quotient >7.8  mg/dl with p  =  0.006 in 
Table 2 Predictive parameters for  definite or probable 
neurosyphilis
Predictive parameters and their p values and odds ratios concerning 
neurosyphilis
* p values are calculated with binary logistic regression
** Coefficient significant (5 %)
Parameter Odds ratio p value*
Serum-RPR-titre ≥32 1.53 0.383
CD4+ cell count ≤350/µl 1.1 0.612
Blood-CSF barrier disturbance in HIV-negatives 9 0.018**
Blood-CSF barrier disturbance in HIV-positives 6 0.027**
Albumin quotient >7.8 mg/dl in HIV-negatives 8.0 0.026**
Albumin quotient >7.8 mg/dl in HIV-positives 23.3 0.006**
Pleocytosis >5 cells/µl in HIV-negatives 6.7 0.006**
Pleocytosis >5 cells/µl in HIV-positives 8.3 0.015**
ITPA index >2 in HIV-negatives 7.6 0.025**
positive IgM-FTA-ABS test in HIV-negatives 13.1 0.022**
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HIV-positives (odds ratio 23.3) and p  =  0.026 in HIV-
negatives (odds ratio 8.0). Another parameter in CSF cor-
relating with definite or probable neurosyphilis in both 
subgroups was a CSF pleocytosis >5 cells/µl (p =  0.015 
and odds ratio 7.3 in HIV-negatives and p =  0.006 and 
odds ratio 9.5 in HIV-positives). A CSF-TPPA ≥1:32 sig-
nificantly correlates with definite or probable neurosyph-
ilis only in the subgroup of HIV-positives (p = 0.003) but 
no longer for HIV-negatives. In contrast to this an ITPA 
index >2 correlates significantly with definite or prob-
able neurosyphilis only in the subgroup of HIV-negatives 
(p = 0.025, odds ratio 8.2). The same applies to a positive 
IgM-FTA-ABS in CSF with p = 0.022 and odds ratio 14.0 
for HIV-negatives.
Considering the subgroups, there was no longer a cor-
relation detectable for local IgG-synthesis.
Sensitivity and specificity of Treponema pallidum testing 
in cerebrospinal fluid
CSF‑RPR test
The RPR test in CSF plays an important role in the diag-
nosis of neurosyphilis and is the gold standard for diag-
nosis of neurosyphilis next to the VDRL test in CSF. In 
our analyzed group of patients with available HIV-status 
and all necessary criteria for the diagnosis of definite or 
probable neurosyphilis (n = 67), the RPR test in CSF has 
a sensitivity of only 21 % and a specificity of 97 % for a 
definite or probable neurosyphilis. Accordingly almost 
80 % of neurosyphilis cases would have been overlooked 
using this test for the diagnosis of neurosyphilis.
The sensitivity of the CSF-RPR based on definite neu-
rosyphilis increases to 31 %. However, this is still very low 
because more than two-thirds of patients with definite 
neurosyphilis would have been overlooked by this test.
If we separate patients with a definite and probable neu-
rosyphilis by their HIV-status the sensitivity of the RPR 
test in CSF would be 22  % in HIV-positive patients and 
20  % in HIV-negatives. Concerning definite neurosyphi-
lis the sensitivity of the RPR test in CSF increases in HIV-
coinfected patients to 33 % and in HIV-negative to 29 %.
CSF‑FTA‑ABS test
The CSF-FTA-ABS is often used to exclude the diagnosis 
of neurosyphilis, since its sensitivity in contrast to CSF-
RPR or CSF-VDRL is approximately 100 %. The specific-
ity has been described with just over 70 % [13, 16].
In our analysis the CSF-FTA-abs showed a sensitivity 
of 89 % and a specificity of 22 %. The criteria used in this 
study to diagnose a definite or probable neurosyphilis 
included clinical symptoms. This test would have failed 
to see three cases we classified as definite or probable 
neurosyphilis. Concerning definite neurosyphilis, which 
is based more on laboratory diagnostic criteria, the sen-
sitivity of the CSF-FTA-abs was 90  % with a specificity 
of 18 %. According to this the CSF-FTA-abs would have 
excluded the diagnosis of neurosyphilis in one patient 
who met our criteria for definite neurosyphilis.
Differentiating the specificity and sensitivity accord-
ing to HIV-status, the CSF-FTA-ABS has a specificity of 
44 % and a sensitivity of 83 % in the diagnosis of definite 
or probable neurosyphilis in the group of HIV-coinfected 
patients. In the group of HIV-negative patients, the sensi-
tivity is 100 % and the specificity only 7 %.
ITPA index
In our study we observed a correlation between an ITPA 
index >2 and neurosyphilis (p =  0.042). However, if we 
discriminate between HIV-positives and -negatives this 
correlation is only detectable in HIV-negative patients 
(p  =  0.025) and not in HIV-positives (p  =  0.448). The 
sensitivity was 54 % and the specificity was 88 % for the 
ITPA index >2 in HIV-negatives for neurosyphilis.
Discussion
We have retrospectively evaluated current diagnostic 
standards for neurosyphilis in HIV-positive and -negative 
patients in patients who were previously diagnosed with 
active syphilis and who had undergone lumbar puncture.
Sensitivity and specificity of cerebrospinal fluid analysis
The CSF-RPR had a sensitivity of 21 % and a specificity of 
97 % in the diagnosis of probable or definite neurosyphi-
lis. This corresponds approximately to the sensitivity 
and specificity of the CSF-VDRL and thus to the results 
of Castro et  al. [10, 11, 17]. We were not able to deter-
mine the sensitivity and specificity of the CSF-VDRL in 
this study because in our population it was the CSF-RPR 
being used instead of the CSF-VDRL. However, a com-
parison between the RPR test used herein and reported 
in the literature with the sensitivity and specificity of CSF 
VDRL test is possible. If the CSF is not visibly contami-
nated with blood, a positive CSF-VDRL is for 100 % spe-
cific with a sensitivity of 27–70 % [10, 11]. The CSF-RPR 
indicated in one study the same sensitivity and specificity 
as the CSF-VDRL, thus both tests are applicable to diag-
nose neurosyphilis [17]. In this study none of the samples 
was visibly contaminated with blood.
CSF-RPR is used for the diagnosis of neurosyphilis, but 
its sensitivity is very low. This raises the question whether 
a test with such a low sensitivity actually should continue 
to be used as a gold standard for neurosyphilis diagnosis, 
if it overlooks almost 80 % of neurosyphilis patients.
Taking the other available tests into account the 
diagnosis of neurosyphilis still remains difficult. The 
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CSF-FTA-abs had in some studies a sensitivity of 100 %, 
but it is not as specific as the CSF-VDRL or -RPR [16, 18]. 
Thus this test seems to be suitable to exclude neurosyphi-
lis. However, these statements are based on common 
laboratory diagnostic definitions of neurosyphilis and 
may not be suitable to exclude neurosyphilis when strong 
clinical suspicion exists [19, 20]. Our data analysis raises 
the suspicion that some cases (3/28, 11 %) of definite or 
probable neurosyphilis would be incorrectly excluded 
since the CSF-FTA-ABS had a sensitivity of 89 % in the 
diagnosis of neurosyphilis. This included one case with 
definite and two cases with probable neurosyphilis.
A positive CSF TPPA test, particularly if it is confirmed 
by an activity parameter, may help to diagnose neuro-
syphilis. This is also suggested by the observation that 
using the German guidelines three potential neurologi-
cally asymptomatic neurosyphilis patients would have 
been overlooked yet all of them had a positive CSF TPPA.
In addition, the ITPA index (sensitivity 84 % specificity, 
100 %) is used in Germany [12]. The ITPA index seems 
to be only usefully applicable in the diagnosis of neuro-
syphilis in HIV-negative patients since there was no cor-
relation in HIV-positive patients between neurosyphilis 
and positive ITPA index.
Unfortunately activity parameters for the confirmation 
of neurosyphilis which have a sufficiently high sensitiv-
ity are lacking. As described above, only the CSF-VDRL, 
CSF-RPR as well as a specific IgM antibody result or 
pleocytosis would be suitable to accomplish this task. 
The VDRL and RPR test have such a low sensitivity that 
they would confirm the activity of neurosyphilis in only 
a few cases. A pleocytosis may be used uncritically only 
in HIV-negative patients since HIV-positives can show 
pleocytosis without having any other infection.
As already described by other authors an increased CSF 
protein concentration can occur in HIV-positive patients 
without neurosyphilis [21]. In our study the mean protein 
concentration in HIV-positives in total was even 128 mg/
dl, which is much higher than the limit of 40 or 50 mg/
dl which is used in the guidelines of the German Society 
for STD diagnosis and treatment of syphilis to identify a 
probable neurosyphilis [12]. An elevated protein concen-
tration in CSF is thus not suitable as a parameter for con-
firmation of neurosyphilis in HIV-positives.
However a disturbed blood-CSF barrier significantly 
correlates with a definite or probable neurosyphilis for 
HIV-positives (p  =  0.027) as well as for HIV-negatives 
(p  =  0.018). The same applies for an albumin quotient 
>7.8 mg/dl with p = 0.006 in HIV-positives and p = 0.026 
in HIV-negatives. These two parameters should be given 
greater consideration for the diagnosis of neurosyphilis.
Clinical manifestation of syphilis in HIV‑positives 
and ‑negatives
In our cohort HIV-coinfected patients had more often 
a primary lesion than HIV-negatives. Unfortunately 
we cannot evaluate the frequent occurrence of mul-
tiple chancres and their persistence in HIV-positives 
retrospectively which was described in literature [22–
24]. Although we found no difference between HIV-
coinfected patients and HIV-negatives concerning the 
spectrum of neurological symptoms, we detected that 
HIV-negatives always presented with neurological symp-
toms, while HIV-positives have been also asymptomatic. 
Altogether 8.6  % of the HIV-positives had a neurologi-
cally asymptomatic neurosyphilis which matches with 
the results of Holtom et  al. who found 9 % of the HIV-
positive patients to have an asymptomatic neurosyphilis 
[25].
All in all our results show that clinical symptoms do not 
differ as much between HIV-positives and -negatives as 
we would have expected. But still the higher incidence of 
neurologically asymptomatic neurosyphilis during HIV-
coinfection shows that these patients are at risk to miss 
a lumbar puncture to provide the right diagnosis and to 
undergo the necessary therapy.
Neuroimaging is also very important as a diagnostic 
parameter for neurosyphilis [26]. Unfortunately we were 
not able to analyse imaging data since two-thirds of the 
patients in our study have not received neuroimaging.
Neurosyphilis, HIV immune status and predictive 
parameters
We tried to ascertain whether a poor or good immune 
status in HIV-coinfected patients, which we defined by 
a number of CD4+  T  cells < or ≥350/μl, increases the 
risk for neurosyphilis or not. Our results show no dif-
ference in these two groups concerning the diagnostic 
parameters but we found out that patients with poor 
immune status had a higher incidence of probable neu-
rosyphilis while patients with better immune status were 
more likely to have a neurologically asymptomatic neu-
rosyphilis. Unfortunately a good or poor immune sta-
tus does not help to predict or exclude the diagnosis of 
neurosyphilis. It is rather apparent that HIV-coinfected 
patients are generally more likely to have neurosyphilis 
and maybe they are even more likely to have an asympto-
matically proceeding disease which should not be missed 
by the physician. The role of a good or poor immune sta-
tus should be explored in further studies.
Furthermore we found neither a correlation between 
immune status and neurosyphilis nor between RPR-titre 
and neurosyphilis. The combination of both parameters 
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also only had a predictive value of 66.7 %. This matches 
with the study of Wang et al. who showed that patients 
who did not meet the criteria of poor CD4+  T  cells or 
RPR-titre ≥1:32 still had neurosyphilis [27]. We admit 
that the difference between our results and those suggest-
ing that poor CD4+ T cells or high serum-RPR-titre are 
predictive for neurosyphilis might be due to the fact that 
we used other criteria for the definition of neurosyphilis.
Altogether our results show that more research con-
cerning diagnostic parameters in serum and cerebrospi-
nal fluid is necessary.
Conclusions
This study indicates that neurosyphilis is still difficult 
to diagnose particularly in asymptomatic patients and 
patients with HIV-coinfection. A spinal tap should be 
an essential part of the diagnostic workup in any patient 
especially in those with HIV coinfection. Our data show 
that a pleocytosis and an elevated albumin quotient cor-
relate with neurosyphilis. However, standard diagnostic 
tests such as the CSF-RPR have a sensitivity that is far too 
low to be reliable in clinical settings.
Authors’ contributions
VM contributed to the study design, data collection, analysis and interpreta-
tion and was responsible for writing. KH contributed to the study design, data 
analysis and interpretation and supervised the writing and review of all ver-
sions of the manuscript. Both authors read and approved the final manuscript.
Author details
1 Group Practice Family Physicians, Alt-Buckow 9-11, 12349 Berlin, Germany. 
2 Department of Neurology, Universitätsmedizin Charité, Charitéplatz 1, 
10117 Berlin, Germany. 
Compliance with ethical guidelines
Competing interests
The authors declare that they have no competing interests.
Received: 15 May 2015   Accepted: 17 September 2015
References
 1. Marra CM. Neurosyphilis. Curr Neurol Neurosci Rep. 2004;4(6):435–40.
 2. Dylewski J, Duong M. The rash of secondary syphilis. CMAJ. 
2007;176(1):33–5.
 3. Frippiat F, et al. Syphilis in 2008: practical aspects and controversies. Rev 
Med Suisse. 2008;4(168):1823–7.
 4. Wolters EC. Treatment of neurosyphilis. Clin Neuropharmacol. 
1987;10(2):143–54.
 5. Ghanem KG, et al. Lumbar puncture in HIV-infected patients with syphilis 
and no neurologic symptoms. Clin Infect Dis. 2009;48(6):816–21.
 6. Stoner BP. Current controversies in the management of adult syphilis. Clin 
Infect Dis. 2007;44(Suppl 3):S130–46.
 7. Buchacz K, et al. Syphilis increases HIV viral load and decreases CD4 
cell counts in HIV-infected patients with new syphilis infections. AIDS. 
2004;18(15):2075–9.
 8. Kent ME, Romanelli F. Reexamining syphilis: an update on epidemiol-
ogy, clinical manifestations, and management. Ann Pharmacother. 
2008;42(2):226–36.
 9. Lynn WA, Lightman S. Syphilis and HIV: a dangerous combination. Lancet 
Infect Dis. 2004;4(7):456–66.
 10. Golden MR, Marra CM, Holmes KK. Update on syphilis: resurgence of an 
old problem. JAMA. 2003;290(11):1510–4.
 11. Davis LE, Schmitt JW. Clinical significance of cerebrospinal fluid tests for 
neurosyphilis. Ann Neurol. 1989;25(1):50–5.
 12. Schofer H, et al. Syphilis. Guideline of the German Sexually Transmitted 
Diseases Society fo diagnosis and therapy of syphilis. J Dtsch Dermatol 
Ges. 2006;4(2):160–77.
 13. Marra CM, et al. Cerebrospinal fluid abnormalities in patients with 
syphilis: association with clinical and laboratory features. J Infect Dis. 
2004;189(3):369–76.
 14. Libois A, et al. HIV and syphilis: when to perform a lumbar puncture. Sex 
Transm Dis. 2007;34(3):141–4.
 15. Ghanem KG, et al. Neurosyphilis in a clinical cohort of HIV-1-infected 
patients. AIDS. 2008;22(10):1145–51.
 16. Marra CM, et al. Alternative cerebrospinal fluid tests to diagnose neuro-
syphilis in HIV-infected individuals. Neurology. 2004;63(1):85–8.
 17. Castro R, Prieto ES, da Luz Martins Pereira F. Nontreponemal tests in 
the diagnosis of neurosyphilis: an evaluation of the Venereal Disease 
Research Laboratory (VDRL) and the Rapid Plasma Reagin (RPR) tests. J 
Clin Lab Anal. 2008;22(4):257–61.
 18. Marra CM, et al. Cerebrospinal fluid treponemal antibodies in untreated 
early syphilis. Arch Neurol. 1995;52(1):68–72.
 19. Marra CM. Update on neurosyphilis. Curr Infect Dis Rep. 
2009;11(2):127–34.
 20. Harding AS, Ghanem KG. The performance of cerebrospinal fluid 
treponemal-specific antibody tests in neurosyphilis: a systematic review. 
Sex Transm Dis. 2012;39(4):291–7.
 21. Farhi D, Dupin N. Management of syphilis in the HIV-infected patient: 
facts and controversies. Clin Dermatol. 2010;28(5):539–45.
 22. Rolfs RT, et al. A randomized trial of enhanced therapy for early syphilis in 
patients with and without human immunodeficiency virus infection. The 
Syphilis and HIV Study Group. N Engl J Med. 1997;337(5):307–14.
 23. Rompalo AM, et al. Clinical manifestations of early syphilis by HIV 
status and gender: results of the syphilis and HIV study. Sex Transm Dis. 
2001;28(3):158–65.
 24. Hutchinson CM, et al. Altered clinical presentation of early syphilis in 
patients with human immunodeficiency virus infection. Ann Intern Med. 
1994;121(2):94–100.
 25. Holtom PD, et al. Prevalence of neurosyphilis in human immuno-
deficiency virus-infected patients with latent syphilis. Am J Med. 
1992;93(1):9–12.
 26. Czarnowska-Cubala M, et al. MR findings in neurosyphilis—a literature 
review with a focus on a practical approach to neuroimaging. Psychiatr 
Danub. 2013;25(Suppl 2):S153–7.
 27. Wang YJ, et al. Syphilis and neurosyphilis in human immunodeficiency 
virus-infected patients: a retrospective study at a teaching hospital in 
Taiwan. J Microbiol Immunol Infect. 2012;45(5):337–42.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
